You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

SMC approval welcome news for breast cancer patients

The SMC has accepted Trodelvy (sacituzumab govitecan) for use in Scotland on the NHS, for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).